Formulation Development
Akston Biosciences Doses First Participants in Phase 2 Clinical Trial for Shelf-Stable COVID-19 Booster
Akston Biosciences Corporation recently announced it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a…
Pneumagen Announces Positive Top Line Results From Phase 1 Study Evaluating a Product Designed for the Prevention & Treatment of Viral Respiratory Tract Infections
Pneumagen recently reported positive topline data from a Phase 1 study with Neumifil designed to evaluate safety and tolerability in healthy volunteers. The Phase 1, single…
NGM Bio Announces Initiation of Phase 1/1b Clinical Study for the Treatment of Patients With Advanced Solid Tumors
NGM Biopharmaceuticals, Inc. recently announced it has initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors. With…
Update on Positive Pre-Clinical Results From AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
Aeterna Zentaris Inc. recently provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals (AIM Biologicals), for the potential treatment of Parkinson’s Disease (PD)…..
Vallon Pharmaceuticals Reports Additional Pharmacokinetic & Pharmacodynamic Data From SEAL Study of ADAIR
Vallon Pharmaceuticals, Inc. recently reported additional results from the SEAL study evaluating the abuse potential of ADAIR. ADAIR is the company’s proprietary abuse-deterrent formulation of…
Artax Biopharma Closes Financing to Advance Clinical-Stage, First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Artax Biopharma, Inc. recently announced the close of a $26-million financing round to develop AX-158, the company’s first oral small molecule immunomodulating agent…..
Cue Biopharma Receives FDA Acceptance of IND Application for CUE-102 in Wilms’ Tumor 1 (WT1) - Expressing Cancers
Cue Biopharma, Inc. recently announced the US FDA has accepted the company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin…
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients With Advanced Solid Tumors
Immatics N.V. recently announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER) IMA401 for patients with recurrent and/or refractory….
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction
Faraday Pharmaceuticals, Inc. recently announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy…
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial
Evaxion Biotech A/S recently announced it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical trial…
AUM Biosciences Enters Collaboration With Roche for Clinical Development of AUM001 in Combination With Anti-PD-L1 Therapy in Solid Tumor Indications
AUM Biosciences recently announced it has entered into a clinical trial collaboration and supply agreement with Roche to evaluate AUM001, the company’s novel, highly selective….
Enteris BioPharma to Exhibit at CPhI North America 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned subsidiary of SWK Holdings Corporation…
Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program
Hovione, the leader in spray drying and particle engineering, recently announced an exclusive license agreement for a preclinical ophthalmology program, JX08, with….
MoonLake Immunotherapeutics Announces Publication of New Long-Term Disease Control Data From Phase 2b Psoriasis Trial
MoonLake Immunotherapeutics AG recently announced the British Journal of Dermatology (BJD) has published a new data analysis, which can be accessed in the BJD online library, from the Phase 2b clinical trial assessing the effect of sonelokimab….
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination With Atezolizumab in Small Cell Lung Cancer
Imago BioSciences, Inc. recently announced the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab (Tencentriq) during…
Lonza & ALSA Ventures Collaborate to Provide Development & Manufacturing Services for Biotech Firms
ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, recently…
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
Entera Bio Ltd. recently announced it recently filed multiple US patent applications to further strengthen the company’s patent protection and support future developments. These patent…
Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics
Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on global net sales of products….
WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments…
WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery
As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….
